Stocktoria
BillionToOne, Inc. BLLN
BillionToOne, Inc. (BLLN) earns a Piotroski F-score of 7/9 (strong financial health), with an Altman Z″ in the safe zone. It does not currently pay a dividend. FY2025 revenue was $305.1M at a 2.4% net margin.
Beneish M-score: -2 — grey zone (between the usual thresholds). A statistical screen for earnings manipulation, not proof — and it doesn't apply to most banks/insurers.
Analyst price target
Recent analyst actions
| Date | Firm | Rating |
|---|---|---|
| 2026-06-29 | Guggenheim | Buy (init) |
| 2026-05-13 | Guggenheim | Buy (main) |
| 2026-05-07 | JP Morgan | Overweight (main) |
| 2026-05-07 | BTIG | Buy (main) |
| 2026-03-30 | Guggenheim | Buy (main) |
| 2026-03-05 | Wells Fargo | Equal-Weight (main) |
Wall Street analyst consensus — a sentiment gauge, not our scoring.
How it ranks in Services · percentile among 982 companies
Percentile vs other Services companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 7/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · safe zone
| Component | Value |
|---|---|
| Working capital / assets | 0.81 |
| Retained earnings / assets | -0.434 |
| EBIT / assets | 0.025 |
| Equity / liabilities | 3.147 |
Sector peers · similar-size Services companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| BLLN | BillionToOne, Inc. | 7/9 | 7.37 | 729.2 | +100% |
| FLGT | Fulgent Genetics, Inc. | 3/9 | 14.37 | — | +13.8% |
| CSTL | CASTLE BIOSCIENCES INC | 3/9 | 6.15 | — | +3.7% |
| CDNA | CareDx, Inc. | 4/9 | 0.16 | — | +13.8% |
| GRAL | GRAIL, Inc. | 4/9 | -2.86 | — | +17.2% |
| VCYT | VERACYTE, INC. | 7/9 | 15.66 | 61.2 | +16% |
| BDSX | BIODESIX INC | 3/9 | -19.59 | — | +24.1% |
About BillionToOne, Inc.
BillionToOne, Inc., a precision diagnostics company, quantifies biology to create molecular diagnostics. The company provides molecular counting platform, which is designed to detect and measure DNA molecules at the single-count level to help enhance disease detection. It also offers UNITY Complete, a non-invasive prenatal screen that assesses fetal risk for aneuploidies, recessive conditions, and fetal antigens from a maternal blood draw; Northstar Select, a liquid biopsy test that provides a list of mutations that are present in the tumor and types of mutations detected that include deletions, insertions, and point mutations; and Northstar Response, a methylation-based assay that quantifies the amount of cancer at the single molecule level without requiring a tissue biopsy, enabling real-time monitoring of patient response to therapy with unprecedented precision. BillionToOne, Inc. was incorporated in 2016 and is headquartered in Menlo Park, California.
FAQ
Is BLLN financially healthy?
BillionToOne, Inc.'s Piotroski F-score is 7/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the safe zone.
Does BLLN pay a dividend?
No, BillionToOne, Inc. does not currently pay a dividend.
How profitable is BLLN?
In FY2025, BillionToOne, Inc. had a net margin of 2.4% and a return on equity of 1.6%.
What is BLLN's P/E ratio?
BillionToOne, Inc.'s trailing price-to-earnings (P/E) ratio is about 729.2×, based on its latest annual earnings.
What is the analyst price target for BLLN?
The average Wall-Street price target for BillionToOne, Inc. is $117.71, about 20.8% above the recent price, from 7 analysts (consensus: buy).
Is BLLN a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on BillionToOne, Inc.: a Piotroski F-score of 7/9, an Altman Z″ in the safe zone, a P/E of about 729.2×. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.